Pluristem to report data from COVID-19 therapy studies in Q4, shares up

Pluri

08/07/2021 13:12

** U.S. shares of Israel-based regenerative medicine co
 PSTI.O  rise 2.5% to $3.69 premarket
    ** Co intends to report topline results from Phase 2 studies
testing its COVID-19 therapy in Q4 
    ** Says it will not go through with its plans to expand its
COVID-19 program to Mexico and will report data only from
patients enrolled to date in the studies conducted in the United
States, Europe and Israel  urn:newsml:reuters.com:*:nGNX1jm5TP
    ** The decision was made in response to COVID-19's evolution
as a disease, as well as changes in the standard of care and a
decline in the most severe cases - co
    ** The Phase 2 studies tested the safety and efficacy of
co's PLX cells for severe COVID-19 cases complicated by Acute
Respiratory Distress Syndrome (ARDS)
    ** PSTI was down 49.1% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))